Danielle Corrigan

[Cancer Letters] Scientists describe the mechanisms by which mitochondrial fragmentation (MF) contributes to HCC development, discuss potential therapeutic approaches, and the possibility that MF modulation has a synergistic effect with immunotherapy.

[GENFIT] GENFIT announced that the US FDA has granted orphan drug designation to GNS5611 (ezurpimtrostat), a novel clinical-stage autophagy/PPT1 inhibitor, for the treatment of cholangiocarcinoma.

[Oncogene] The authors found that expression of miR-7, regulated by p53, was lower in prostate cancer tissues, and miR-7 overexpression significantly mitigated prostate cancer cells growth both in vitro, in organoids, and in vivo regardless of p53 status.

[Nature Communications] To improve our understanding of enza resistance, the authors analyzed the transcriptomes of matched biopsies from men with metastatic CRPC obtained prior to treatment and at progression.

[Journal of Reproductive Immunology] Researchers conducted a cross-sectional study among early onset preeclampsia, late onset preeclampsia, and normotensive pregnancies. The number of decidual dendritic cell-10 and Treg cells were counted using flow cytometry.

[Cell & Bioscience] The authors summarize the categories and development of liver organoids, and focus on the functions of culture medium components and applications of organoids for hepatitis B virus infection and associated liver cancer studies.